masimo corp (MASI) Key Developments
Masimo Receives CE Mark and Full Market Release of MightySat™ Rx Fingertip Pulse Oximeter for Clinical Use in CE Countries
Jun 22 15
Masimo announced the CE Mark and full market release of MightySat™ Rx fingertip pulse oximeter for clinical use in CE countries, offering the same Masimo SET® Measure-Through Motion and Low Perfusion™ pulse oximetry technology used in hospitals. MightySat™ Rx fingertip pulse oximeter provides oxygen saturation (SpO2), pulse rate (PR), Perfusion Index (PI), and Pleth Variability Index (PVI®). Bluetooth®-enabled versions of MightySat Rx allow clinicians to track and trend up to 12 hours of patient measurements on smart mobile devices, and to share that data via standard CSV files as well as transfer to Apple’s Health app. MightySat Rx enables accurate noninvasive spot-checking of oxygen saturation (SpO2) and pulse rate (PR) for adult and paediatric patients even during motion and low perfusion. MightySat Rx measures and displays Perfusion Index (PI), which reflects the strength of the pulsatile signal. MightySat can also measure and display Pleth Variability Index (PVI®), a measure of the dynamic changes in the perfusion index that occur during one or more complete respiratory cycle/s. MightySat Rx is available in three versions for patients who weigh more than 30 kg (66 lbs): MightySat Rx " Measures and displays SpO2, PR, and PI. MightySat Rx, Bluetooth " Adds Bluetooth LE radio for transfer of parameter data to Apple iOS® and select Android™ mobile devices. MightySat Rx, Bluetooth and PVI. Standard features include: Measure-Through Motion and Low Perfusion performance. Signal I.Q.® to assess measurement confidence. Rugged, lightweight design for operation in challenging environments. Long battery life 'up to 15 hours with two standard AAA alkaline batteries. Comfortable design with silicon finger pad to mold to patients’ fingers.
Masimo Corporation Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 04:00 PM
Jun 2 15
Masimo Corporation Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-09-2015 04:00 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Mark P. de Raad, Chief Financial Officer and Executive Vice President of Finance.
Masimo Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended April 4, 2015; Provides Earnings Guidance for the Full Year of 2015
May 6 15
Masimo Corporation reported unaudited consolidated earnings results for the first quarter ended April 4, 2015. For the quarter, total revenue was $154,537,000 against $139,814,000 a year ago. Operating income was $27,377,000 against $30,193,000 a year ago. Income before provision for income taxes was $27,530,000 against $30,393,000 a year ago. Net income attributable to the company stockholders was $20,523,000 against $22,632,000 a year ago. Diluted net income per share attributable to the company stockholders was $0.38 against $0.39 a year ago. Net cash provided by operating activities was $19,124,000 against $24,226,000 a year ago. Purchases of property and equipment were $17,218,000 against $3,045,000 a year ago. Increase in intangible assets was $679,000 against $886,000 a year ago. Non-GAAP total revenue was $158,773,000 against $139,814,000 a year ago. Non-GAAP operating income was $29,354,000 against $22,571,000 a year ago. Non-GAAP income before provision for income taxes was $29,073,000 against $22,771,000 a year ago. Non-GAAP net income attributable to the company stockholders was $22,171,000 against $17,902,000 a year ago. Non-GAAP net income per share attributable to the company stockholders was $0.41 against $0.31 a year ago.
The company is updating its 2015 financial guidance. The company now expects fiscal 2015 total revenues to be $608 million, up from $605 million and total product revenues to be $580 million, up from $577 million. The company now also expects its GAAP earnings per diluted share to be $1.33, up from $1.30 and expects non-GAAP earnings per diluted share to be approximately $1.48. The company is projecting fiscal 2015 EBITDA to be approximately $115 million to $120 million.
Masimo Corporation, Annual General Meeting, Jun 02, 2015
May 4 15
Masimo Corporation, Annual General Meeting, Jun 02, 2015., at 14:00 Pacific Standard Time. Location: 40 Parker. Agenda: To elect the following nominee as a Class II director to serve until 2018 annual meeting of stockholders: Mr. Joe Kiani; to elect the following nominee as a Class II director to serve until 2018 annual meeting of stockholders: Mr. Joe Kiani; to vote on an advisory resolution to approve named executive officer compensation; and to conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
Masimo Corporation to Report Q1, 2015 Results on May 06, 2015
Apr 22 15
Masimo Corporation announced that they will report Q1, 2015 results After-Market on May 06, 2015